Gynecologic Oncology Reports最新文献

{"title":"Cervical adenocarcinoma presenting as an ovarian torsion","authors":"M. Mvula ,&nbsp;S. Roychoudhury ,&nbsp;K. King ,&nbsp;N. Aravindan ,&nbsp;C. Chan ,&nbsp;V. John ,&nbsp;J. Whyte ,&nbsp;GL. Goldberg","doi":"10.1016/j.gore.2024.101546","DOIUrl":"10.1016/j.gore.2024.101546","url":null,"abstract":"<div><h3>Background</h3><div>Cervical adenocarcinoma is increasing in incidence and can rarely present as ovarian metastasis.</div><div>Case: A 41-year-old female who presented with left lower quadrant pain and vomiting. Intra-operative findings revealed bilateral ovarian cysts with initial pathology results of mucinous ovarian adenocarcinoma. Final histopathology revealed an invasive poorly differentiated mucinous adenocarcinoma of the cervix.</div></div><div><h3>Conclusions</h3><div>Mucinous adenocarcinoma in the ovary is usually a metastasis and an extensive and comprehensive work-up is required to try to locate the primary tumor.</div><div>Précis: Mucinous adenocarcinoma in the ovary is usually a metastasis and an extensive and comprehensive work-up is required to try to locate the primary tumor.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"56 ","pages":"Article 101546"},"PeriodicalIF":1.2,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142697597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy","authors":"Brittany File ,&nbsp;Anjali Hari ,&nbsp;Ling Bei","doi":"10.1016/j.gore.2024.101547","DOIUrl":"10.1016/j.gore.2024.101547","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"56 ","pages":"Article 101547"},"PeriodicalIF":1.2,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142697598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant struma ovarii in pregnancy: A case report","authors":"Raveena Kapoor ,&nbsp;Monalisa Sur ,&nbsp;Julie M.V. Nguyen","doi":"10.1016/j.gore.2024.101541","DOIUrl":"10.1016/j.gore.2024.101541","url":null,"abstract":"<div><h3>Introduction</h3><div>Struma ovarii are a rare type of cystic teratomas that are composed predominantly or entirely of thyroid tissue and account for less than 1 % of all ovarian tumours. Malignant presentations are even less common, accounting for approximately 5 % of struma ovarii. Due to their rarity, evidence to inform management is very limited. We report a distinctive case of a 27 year-old patient with malignant struma ovarii (MSO) during pregnancy.</div></div><div><h3>Case Presentation</h3><div>The patient presented with acute lower abdominal pain and was treated with a laparoscopic cystectomy for ovarian torsion. Pathology revealed a 3 cm MSO with a component of papillary thyroid carcinoma arising in an 11.2 cm mature cystic teratoma. The patient became pregnant while pathology results were pending. Given the absence of most high-risk features such as presence of surface adhesions, tumor size greater than 5–10 cm, ascites greater than 1 L, or extra-capsular extension, she was deemed suitable for close observation during pregnancy with serial ultrasounds. At term, she underwent an elective repeat cesarean section, with a concomitant completion unilateral salpingo-oophorectomy and omentectomy. Four months later, a recurrence was detected in the abdominal and pelvic lymph nodes, which was managed with cytoreductive surgery and total thyroidectomy, followed by radioactive iodine (RAI) therapy. Three years after her initial diagnosis, the patient remains well without biochemical or radiologic evidence of recurrence.</div></div><div><h3>Discussion</h3><div>MSO are rare and treatment should be individualized. In select cases, fertility-sparing management can be considered. The role of thyroidectomy and RAI therapy remains a topic of debate.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"56 ","pages":"Article 101541"},"PeriodicalIF":1.2,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142662517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vulvar squamous cell carcinoma: The role of p53 and p16 immunohistochemistry","authors":"Helena M Obermair ,&nbsp;James Elhindi ,&nbsp;Alison Brand ,&nbsp;Unine Herbst","doi":"10.1016/j.gore.2024.101544","DOIUrl":"10.1016/j.gore.2024.101544","url":null,"abstract":"<div><div>Vulvar squamous cell carcinomas (SCC) represent a heterogeneous group of patients with implications for prognosis and response to treatment. Human papillomavirus (HPV)-associated SCC is characterised by p16 positivity, whereas non-HPV SCC often shows aberrant p53 expression. We conducted a retrospective analysis involving 148 patients with vulvar SCC from two Gynecologic Oncology units from Sydney, Australia. Patients’ demographics, tumor characteristics, types of treatment and survival were analyzed and compared to p16 and p53 immunohistochemistry status. The p16-positive group was younger and included a higher prevalence of smokers, while the p53-positive group demonstrated greater comorbidity indices and was associated with tumor features that are independently related to poor prognosis. Compared to p16-positive patients our study has shown significantly higher recurrence rates and lower overall survival in the p53-positive group. Our findings support existing literature, emphasizing the prognostic significance of p16 and p53 in vulvar SCC. Despite the retrospective nature and variations in immunohistochemistry reporting, our study provides valuable insights into patient outcomes, particularly in a demographically diverse population. Future research, like the STRIVE trial, may determine if implementation of p16 and p53 stratified management algorithm will improve outcomes for women with vulvar SCC (<span><span>McAlpine, 2024</span></span>).</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"56 ","pages":"Article 101544"},"PeriodicalIF":1.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142662518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extraskeletal Ewing sarcoma with uterine cornua attachment mimicking high grade endometrial stromal sarcoma: A case report and brief literature review","authors":"Wangpan Shi ,&nbsp;Somaye Zare ,&nbsp;Cheryl Saenz ,&nbsp;Omonigho Aisagbonhi","doi":"10.1016/j.gore.2024.101537","DOIUrl":"10.1016/j.gore.2024.101537","url":null,"abstract":"<div><h3>Background</h3><div>Ewing sarcoma is an EWSR1-rearranged aggressive malignancy that occurs commonly in bone and has small round blue cell morphology. A diagnostic challenge is presented in the cases of extraskeletal Ewing sarcoma involving solid organs, such as the uterus.</div></div><div><h3>Case report and brief literature review</h3><div>We present the case of a 54-year-old female with<!--> <!-->a large pelvic mass connected to the uterine cornua and retroperitoneal soft tissue. Upon surgical debulking, the mass was characterized by infiltrative tumor cells with high nuclei-to-cytoplasmic ratio invading from the serosal surface into the myometrium. The initial diagnostic work-up was muddied by radiographic suggestion of uterine origin, histologic identification of uterine involvement and diffuse positivity for Cyclin D1, KIT and CD99, which raised the diagnostic possibility of high-grade endometrial stromal sarcoma.<!--> <!-->However, molecular testing that revealed <em>EWSR1::FLI</em> fusion, indicative of Ewing sarcoma. She was thus referred from the gynecologic oncology service to the soft tissue sarcoma service for adjuvant chemotherapy of vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide (VDC/IE). We performed a literature review highlighting immunohistochemical and molecular features along with treatment and outcomes in case series of YWHAE-rearranged high-grade endometrial stromal sarcomas and Ewing sarcoma with uterine and/or retroperitoneal involvement.</div></div><div><h3>Conclusion</h3><div>This case and accompanying literature review highlight the benefit of molecular testing in the context of round cell tumors involving the uterus and the importance of distinguishing high-grade uterine stromal sarcomas from sarcomas of soft tissue origin, as they have different treatment strategies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"56 ","pages":"Article 101537"},"PeriodicalIF":1.2,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142662516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent Low-grade endometrial stromal sarcoma metastasized to the common iliac veins, extending into the inferior vena cava and right atrium after 12 years: A case report","authors":"Nour Naaman ,&nbsp;Mohammad Alyafi ,&nbsp;Heitham Albeshri ,&nbsp;Ahmed A Jamjoom ,&nbsp;Samira AlTurkistany ,&nbsp;Haneen Al-Maghrabi ,&nbsp;Saeed Baradwan","doi":"10.1016/j.gore.2024.101543","DOIUrl":"10.1016/j.gore.2024.101543","url":null,"abstract":"<div><h3>Introduction</h3><div>Extrauterine recurrent metastasis of Low-grade endometrial stromal sarcoma (LG-ESS) to major blood vessels is largely rare with few reported cases.</div></div><div><h3>Case</h3><div>Herein, we present a case of a 51-year-old female with recurrent LG-ESS that has metastasized after 12 years to the inferior vena cava (IVC) and extended into the right atrium and common iliac veins. Computed tomography showed an intracardiac larger thrombus within the right atrium extending into the inferior vena cava and common iliac veins. The patient underwent cytoreduction of the intravenous tumor. Final histopathology confirmed metastatic LG-ESS. Follow-up CT scan after six months showed no residual or recurrence.</div></div><div><h3>Conclusion</h3><div>Treatment for extrauterine metastasis from LG-ESS prioritizes reducing tumor burden through surgical resection and may require collaboration across disciplines. Follow-up hormonal therapy with progestins or aromatase inhibitors significantly impacts patient prognosis.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"56 ","pages":"Article 101543"},"PeriodicalIF":1.2,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142662405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraosseous hibernoma in a patient with vaginal cancer: Case report with radiologic and pathologic correlation","authors":"Ashley Zhang ,&nbsp;Emily Nesbit ,&nbsp;Sarah Erickson ,&nbsp;Linda Duska ,&nbsp;Michael Crawford ,&nbsp;Kara Romano","doi":"10.1016/j.gore.2024.101542","DOIUrl":"10.1016/j.gore.2024.101542","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"56 ","pages":"Article 101542"},"PeriodicalIF":1.2,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142662404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When ovarian mature teratoma peritonitis mimics cancer: What is the best treatment?","authors":"Madison Klavans ,&nbsp;Sarah E. Podwika ,&nbsp;Michael Crawford ,&nbsp;Paola A. Gehrig","doi":"10.1016/j.gore.2024.101539","DOIUrl":"10.1016/j.gore.2024.101539","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"56 ","pages":"Article 101539"},"PeriodicalIF":1.2,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Rates of Germline Pathogenic Variants in Somali Patients with Ovarian Cancer","authors":"José V. Somohano-Short ,&nbsp;Natasha Crawford ,&nbsp;Mahmoud A. Khalifa ,&nbsp;Britt K. Erickson","doi":"10.1016/j.gore.2024.101538","DOIUrl":"10.1016/j.gore.2024.101538","url":null,"abstract":"<div><div>The objective of this study was to determine the rate of germline high risk ovarian cancer susceptibility pathogenic variants in Somali patients with ovarian carcinoma treated at a single institution between 2015 and 2022. Out of eight identified patients, five underwent germline and/or somatic testing, revealing a high prevalence (3 of 5, 60 %) of a BRIP1 splice site mutation (c.1936 + 1G &gt; A). Additionally, one patient had a BRCA2 pathogenic variant, and two had the same MLH1 variant of uncertain significance. The high prevalence of BRIP1 pathogenic variants warrants further study into a possible founder effect within the Somali population, emphasizing the need for targeted genetic screening and counseling. The study also highlights significant barriers to genetic testing, pointing to the critical role of healthcare disparities and social determinants of health (SDoH) in cancer outcomes. Comprehensive genomic profiling and community-based research are essential to address these disparities and improve cancer care for this underserved population. Larger studies are needed to validate these findings and to develop tailored interventions that enhance the prevention, diagnosis, treatment, and prognosis of ovarian cancer in Somali women.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"56 ","pages":"Article 101538"},"PeriodicalIF":1.2,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142553748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep characteristics and recurrence in platinum-sensitive ovarian cancer survivors: A prospective cohort study","authors":"Mélanie Benoit ,&nbsp;Marie-Pierre Sylvestre ,&nbsp;Geetanjali Datta ,&nbsp;Lucy Gilbert ,&nbsp;Vikki Ho ,&nbsp;Igor Karp ,&nbsp;Julie Lacaille ,&nbsp;Susie Lau ,&nbsp;Vanessa Samouëlian ,&nbsp;Anita Koushik","doi":"10.1016/j.gore.2024.101540","DOIUrl":"10.1016/j.gore.2024.101540","url":null,"abstract":"<div><h3>Objective</h3><div>To describe characteristics of sleep (quality, duration, efficiency, and insomnia) in a cohort of high-grade epithelial ovarian cancer (EOC) survivors who have completed and responded to first-line chemotherapy, and to explore their relationships with disease recurrence.</div></div><div><h3>Methods</h3><div>In this cohort of 97 women, sleep and other factors were assessed at baseline and 4 months later. The distribution of participants by categories of sleep characteristics were calculated. Hazard ratios (HRs) and 95 % confidence intervals (95 % CI) for the association between each sleep characteristic and recurrence were estimated using the Cox proportional hazards model, and adjusted for confounding using propensity scores. Associations were estimated for all women and among those defined as fully platinum-sensitive.</div></div><div><h3>Results</h3><div>At baseline, just over half of participants (52.6 % to 56.7 %) had poor sleep quality, efficiency and duration, while most (62.9 %) did not experience insomnia. Distributions remained similar 4 months later. During follow-up, 47 recurrences occurred. Among all participants, HRs (95 % CIs) of recurrence were close to the value of 1, indicating no association, for sleep quality and efficiency, 1.22 (0.66–2.23) for not meeting vs. meeting sleep duration guidelines and 0.68 (0.34–1.39) for the presence vs. absence of insomnia. In fully platinum-sensitive women, the HRs (95 % CIs) were 1.50 (0.64–3.53) for not meeting duration guidelines, 1.25 (0.56–2.79) for poor sleep efficiency, 1.44 (0.55–3.72) for the presence of insomnia, and remained null for sleep quality.</div></div><div><h3>Conclusion</h3><div>Most EOC survivors have poor sleep quality, duration, and efficiency. Research with larger sample sizes is required to better understand the relationship between these sleep characteristics and the risk of recurrence.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"56 ","pages":"Article 101540"},"PeriodicalIF":1.2,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142573105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}